Coloplast A/S (COLO_B) Reports 6% Organic Growth and 4% EBIT Growth

What happened

Coloplast reported 6% organic growth for FY 2025/26. EBIT growth before special items was 4% in constant currencies, which means excluding currency swings. Reported DKK revenue grew 4%, held back by a 2-percentage-point negative currency impact, and Ostomy Care reached 20% US market share.

Confirmed

Global impact / market context

Profit growth of 4% trailing organic growth of 6% suggests costs or currency effects absorbed part of the sales gain, which matters for profit per sale. Currency swings also held reported revenue below underlying demand, so investors must separate real growth from currency effects.

Analyst inference

Results were broadly in line with guidance updated in April 2026, so the release offers little surprise versus expectations. Attention now shifts to FY 2026/27 guidance and a revised 2030 financial ambition referenced in the report, whose figures were not included in the release text.

Analyst inference

What to watch

1. The report says the next catalyst is FY 2026/27 guidance and a revised 2030 financial ambition, but the figures for both are not included in this release text. Confirmed
2. Watch whether the revised 2030 ambition sets explicit targets for organic growth and EBIT growth, since profit growth trailed sales growth this year at 4% versus 6%. Proposed
3. Track currency effects into next year: a 2-percentage-point negative impact reduced reported DKK revenue growth to 4%, so easing currency pressure could lift reported revenue without faster underlying sales. Analyst inference

Evidence

• globenewswire.com